Adiposity, inflammation, genetic variants and risk of post-menopausal breast cancer findings from a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design approach

Table 6 Adjusted estimated risk of post-menopausal breast cancer relative to the reference group, defined as women with no history of exposure to hormonal replacement therapy (HRT) and absence of medical documentation of clinical signs of metabolic syndrome (MetS); C-Statistic = 0.77

Risk factors	Cases	ControlsW	OR (95% CI)¹	P-value
Risk factors	N = 146	N = 613	OR (95% CI)¹	P-value
GHSR (rs2922126)				.02
T/T and A/T	137	532	1.00
A/A	9	81	.4 (.18-.89)
MAP3K1
(rs889312 )
A/A and A/C	125	573	1.00	.008
C/C	21	40	2.41 (1.25-4.63)
Age	146	613	.98 (.95-.99)	.02
Family History of Breast Cancer				.02
Yes	17	34	2.22 (1.14-4.43)
No	129	579	2.22 (1.14-4.43)
Risk Factors
Reference Group	37	384	1.00	< 0.001
HRT	70	213	3.35 (2.15-5.21)	< 0.001
MetS	12	9	14.83 (5.63-39.08)	< 0.001
HRT and MetS	27	7	39.38 (15.71-98.70)